CClinicalTrials.gg
CompletedNCT05697666Updated Jan 26, 2023

Impact of the Depth of Neuromuscular Blockade on Respiratory Mechanics in Moderate to Severe ARDS Patients

An observational study in Acute Respiratory Distress Syndrome and Ventilator-Induced Lung Injury, sponsored by Centre Hospitalier de Saint-Brieuc. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Centre Hospitalier de Saint-Brieuc · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
33
Ages
18 Years and older
Sex
All
01

Study summary

Neuromuscular blockade (NMB) is proposed in patients with moderate to severe acute respiratory distress syndrome (ARDS). The supposed benefit of these muscle relaxants could be partly linked to their effects on respiratory mechanics by reducing ventilator induced lung injuries (VILI), especially the so called atelectrauma. Although its monitoring is recommended in clinical practice, data about the depth of NMB necessary for an effective relaxation of the thoracic and diaphragmatic muscles and, therefore, the reduction of the chest wall elastance, are scarce. The investigators hypothesised that complete versus partial NMB can modify respiratory mechanics and its partitioning.

Read the detailed description

The investigators conducted a prospective study to compare the respiratory mechanics of patients with moderate to severe ARDS according to the NMB depth, using an oesophageal pressure catheter (NutriVent®, Sidam) for transpulmonary pressure (PL) assessment, and facial train of four (TOF) for neuromuscular blockade monitoring. The oesophageal balloon was calibrated according to the method recently described to estimate the individual target volume which is assumed to be more adequate. Each patient was analysed at two different times: deep NMB (TOF = 0) and intermediate to light NMB (TOF > 0). The mechanical ventilation parameters were identical for these two measurements. The primary endpoint was the proportion of patients with expiratory transpulmonary pressure (PLexp) greater than or equal to 0 according to the NMB level, in order to assess the risk of region-dependent atelectasis and alveolar opening/closing injury (atelectrauma). Secondary endpoints included: the impact of the depth of NMB on other partition parameters of respiratory mechanics, and the variability of results according to the type of oesophageal balloon calibration.

02

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Ventilator-Induced Lung Injury

Keywords

  • Oesophageal pressure
  • Transpulmonary pressure
  • Train of four
  • Neuromuscular blockade
03

In context

Respiratory Distress Syndrome

1,597 studies on the registry are indexed under Respiratory Distress Syndrome; 312 are open to participants now.

This study's enrollment of 33 is below the median of 100 across 540 observational studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Centre Hospitalier de Saint-Brieuc is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population includes mainly pulmonary ARDS with a predominance of SARS-CoV2 pneumonia

Inclusion criteria

  • Moderate to severe ARDS patients with PaO2/FiO2 ratio \< 150 mmHg
  • Mechanical ventilation, deep sedation and neuromuscular blockade with continuous infusion of cisatracurium for more than 24 hours
  • Presence of an oesophageal catheter
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • contraindication of oesophageal catheter
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
33 participants (actual)
Patient registry
No

Groups and cohorts

  • Moderate to severe ARDS adult patients under mechanical ventilation and neuromuscular blockade

    no intervention

    Other: Modulation of the depth of the neuromuscular blockade

Interventions

  • OtherModulation of the depth of the neuromuscular blockade

    Analysis of the respiratory mechanics at two times: * Facial train of four = 0, indicating a deep neuromuscular blockade * Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade

06

What researchers measure

Primary outcomes

  1. Proportion of patients with expiratory transpulmonary pressure greater than or equal to 0

    Proportion of patients with expiratory transpulmonary pressure greater than or equal to 0 according to the level of neuromuscular blockade (%)

    Time frame: one day

Secondary outcomes

  1. Inspiratory transpulmonary pressure

    Inspiratory transpulmonary pressure according to the level of neuromuscular blockade (cmH20)

    Time frame: one day

  2. Respiratory system compliance

    Respiratory system compliance according to the level of neuromuscular blockade (ml/cmH20)

    Time frame: one day

  3. Chest wall elastance

    Chest wall elastance according to the level of neuromuscular blockade (cmH2O/l)

    Time frame: one day

  4. Pulmonary elastance

    Pulmonary elastance according to the level of neuromuscular blockade (cmH2O/l)

    Time frame: one day

  5. Driving pressure

    Driving pressure according to the level of neuromuscular blockade (cmH20)

    Time frame: one day

  6. Transpulmonary driving pressure

    Transpulmonary driving pressure according to the level of neuromuscular blockade (cmH20)

    Time frame: one day

  7. Plateau pressure

    Plateau pressure according to the level of neuromuscular blockade (cmH20)

    Time frame: one day

  8. Oesophageal balloon calibration

    Proportion of patients with expiratory transpulmonary pressure greater than or equal to 0 according to the oesophageal balloon calibration volume (%)

    Time frame: one day

07

Study locations

1 site
  • Centre Hospitalier de Saint Brieuc
    Saint-Brieuc, Brittany 22000, France
08

References and documents

Publications

  • Akoumianaki E, Maggiore SM, Valenza F, Bellani G, Jubran A, Loring SH, Pelosi P, Talmor D, Grasso S, Chiumello D, Guerin C, Patroniti N, Ranieri VM, Gattinoni L, Nava S, Terragni PP, Pesenti A, Tobin M, Mancebo J, Brochard L; PLUG Working Group (Acute Respiratory Failure Section of the European Society of Intensive Care Medicine). The application of esophageal pressure measurement in patients with respiratory failure. Am J Respir Crit Care Med. 2014 Mar 1;189(5):520-31. doi: 10.1164/rccm.201312-2193CI. PubMed 24467647 ↗
  • Alhazzani W, Belley-Cote E, Moller MH, Angus DC, Papazian L, Arabi YM, Citerio G, Connolly B, Denehy L, Fox-Robichaud A, Hough CL, Laake JH, Machado FR, Ostermann M, Piraino T, Sharif S, Szczeklik W, Young PJ, Gouskos A, Kiedrowski K, Burns KEA. Neuromuscular blockade in patients with ARDS: a rapid practice guideline. Intensive Care Med. 2020 Nov;46(11):1977-1986. doi: 10.1007/s00134-020-06227-8. Epub 2020 Oct 26. PubMed 33104824 ↗
  • Guervilly C, Bisbal M, Forel JM, Mechati M, Lehingue S, Bourenne J, Perrin G, Rambaud R, Adda M, Hraiech S, Marchi E, Roch A, Gainnier M, Papazian L. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med. 2017 Mar;43(3):408-418. doi: 10.1007/s00134-016-4653-4. Epub 2016 Dec 24. PubMed 28013329 ↗
  • Baedorf Kassis E, Train S, MacNeil B, Loring SH, Talmor D. Monitoring of neuromuscular blockade: a comparison of train-of-four and the Campbell diagram. Intensive Care Med. 2018 Dec;44(12):2305-2306. doi: 10.1007/s00134-018-5420-5. Epub 2018 Oct 22. No abstract available. PubMed 30350170 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05697666
Lead sponsor
Centre Hospitalier de Saint-Brieuc
Responsible party
Nicolas Barbarot (Principal investigator. MD, Intensive Care Unit, Centre Hospitalier de Saint-Brieuc, Centre Hospitalier de Saint-Brieuc) — Principal investigator
First posted
Jan 26, 2023
Start date
Feb 1, 2020
Primary completion
Feb 1, 2022
Completion
Feb 28, 2022
Last update
Jan 26, 2023

Study contacts

Nicolas BARBAROT, MD
principal investigator · Centre Hospitalier Saint Brieuc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion